Pfizer Total Assets 2010-2023 | PFE
Pfizer total assets from 2010 to 2023. Total assets can be defined as the sum of all assets on a company's balance sheet.
- Pfizer total assets for the quarter ending December 31, 2023 were $226.501B, a 14.86% increase year-over-year.
- Pfizer total assets for 2023 were $226.501B, a 14.86% increase from 2022.
- Pfizer total assets for 2022 were $197.205B, a 8.67% increase from 2021.
- Pfizer total assets for 2021 were $181.476B, a 17.67% increase from 2020.
Pfizer Annual Total Assets
(Millions of US $) |
| 2023 |
$226,501 |
| 2022 |
$197,205 |
| 2021 |
$181,476 |
| 2020 |
$154,229 |
| 2019 |
$167,594 |
| 2018 |
$159,422 |
| 2017 |
$171,797 |
| 2016 |
$171,615 |
| 2015 |
$167,381 |
| 2014 |
$167,566 |
| 2013 |
$172,101 |
| 2012 |
$185,798 |
| 2011 |
$188,002 |
| 2010 |
$195,014 |
| 2009 |
$212,949 |
Pfizer Quarterly Total Assets
(Millions of US $) |
| 2023-12-31 |
$226,501 |
| 2023-09-30 |
$215,021 |
| 2023-06-30 |
$220,168 |
| 2023-03-31 |
$195,617 |
| 2022-12-31 |
$197,205 |
| 2022-09-30 |
$195,350 |
| 2022-06-30 |
$195,290 |
| 2022-03-31 |
$183,841 |
| 2021-12-31 |
$181,476 |
| 2021-09-30 |
$179,188 |
| 2021-06-30 |
$169,920 |
| 2021-03-31 |
$158,818 |
| 2020-12-31 |
$154,229 |
| 2020-09-30 |
$178,983 |
| 2020-06-30 |
$177,934 |
| 2020-03-31 |
$166,336 |
| 2019-12-31 |
$167,594 |
| 2019-09-30 |
$170,446 |
| 2019-06-30 |
$156,199 |
| 2019-03-31 |
$155,421 |
| 2018-12-31 |
$159,422 |
| 2018-09-30 |
$167,838 |
| 2018-06-30 |
$164,980 |
| 2018-03-31 |
$164,612 |
| 2017-12-31 |
$171,797 |
| 2017-09-30 |
$172,151 |
| 2017-06-30 |
$168,558 |
| 2017-03-31 |
$168,784 |
| 2016-12-31 |
$171,615 |
| 2016-09-30 |
$178,430 |
| 2016-06-30 |
$170,658 |
| 2016-03-31 |
$162,929 |
| 2015-12-31 |
$167,381 |
| 2015-09-30 |
$170,867 |
| 2015-06-30 |
$160,878 |
| 2015-03-31 |
$160,640 |
| 2014-12-31 |
$167,566 |
| 2014-09-30 |
$171,362 |
| 2014-06-30 |
$172,612 |
| 2014-03-31 |
$171,808 |
| 2013-12-31 |
$172,101 |
| 2013-09-30 |
$175,521 |
| 2013-06-30 |
$179,335 |
| 2013-03-31 |
$187,398 |
| 2012-12-31 |
$185,798 |
| 2012-09-30 |
$182,603 |
| 2012-06-30 |
$182,842 |
| 2012-03-31 |
$185,683 |
| 2011-12-31 |
$188,002 |
| 2011-09-30 |
$196,132 |
| 2011-06-30 |
$195,899 |
| 2011-03-31 |
$194,956 |
| 2010-12-31 |
$195,014 |
| 2010-09-30 |
$191,415 |
| 2010-06-30 |
$191,071 |
| 2010-03-31 |
$195,113 |
| 2009-12-31 |
$212,949 |
| 2009-09-30 |
$141,294 |
| 2009-06-30 |
$139,339 |
| 2009-03-31 |
$122,932 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$146.433B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
